Skip to main content
Equibles
ADPT logo

ADPT · Adaptive Biotechnologies Corp

Track ADPT — free

Use ADPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.94 +0.04 (+0.14%)
Russell 2000 member Rebalance outlook locked
Market Cap
$4.52B
Shares
159.60M
Volume · Sep 30 1.51M Avg daily vol (55 sessions) 2.36M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$28.90 Open$28.80 Day$28.75–29.52 Since split$21.86–29.57 Avg vol 30d2.1M Short int13.5M · 8.5% float · 7.9d Short vol51% Last earningsJul 29, 2026 DataJul 2026–Sep 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Jul 15, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jul 15, 2026.

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 4 wks
Latest filing: 10-Q
filed Aug 4, 2026
Q2 2026 earnings call transcript
call held Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$308.08M
Trailing 12 months
Net income (TTM)
−$63.85M
Trailing 12 months
Revenue growth YoY
+21.5%
Year over year
Operating margin
-12.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$169.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.1%
Year over year · more shares
Price change (1Y)
+113.7%
Trailing year
Short interest
8.5%
Latest settlement · 7.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Limited Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +14%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 91%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+1% holders QoQ · +49 funds added
Insider flow Distributing
Net -$19.0M over 90 days · 100% sells
Short interest Rising
8.45% of float · ▲ +15.2% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
301 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
Revenue growth +55%
Y/Y
EPS growth +64%
Y/Y
Free cash flow $-48.9M
Balance sheet $60.7M
net debt
Quant / Vol
risk profile
High
Volatility 47%
annualized · 1-yr
Max drawdown −8%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the Earnings Call filed Jul 29, 2026
MRD clinical testing volume growth · full year 2026 Initiated 38% – 40%
Operating expense · full year 2026 Initiated $350M – $355M
Guided vs delivered · last 2 settled
Full year revenue full year 2022
guided $185M – $195M
$185.31M In line
Full year revenue full year
guided $148M – $155M
$154.34M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+14% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
91% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+1% holders QoQ · +49 funds added
Insider flow Distributing
Net -$19.0M over 90 days · 100% sells
Short interest Rising
8.45% of float · ▲ +15.2% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
301 holders — near 3-yr high, broad support
Price context
position in its range since split · 2026-07-15
Range low $22 Now $29 · 91% Range high $30
vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADPT
Adaptive Biotechnologies Corp
this stock
$4.52B — +54.8% — 8.5%
TMO
Thermo Fisher Scientific Inc.
 $249.58B +16.5% +14.5% 36.3 1.4%
DHR
Danaher Corp /De/
 $155.42B -3.2% +8.5% 39.2 1.2%
NTRA
Natera, Inc.
 $59.47B +80.4% -2.8% — 3.3%
A
Agilent Technologies, Inc.
 $48.90B +26.6% +6.4% 34.2 1.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
301
% held
101.9%
Net QoQ
+10.6M sh
Top holder
VIKING GLOBAL INVESTORS LP
Held Float
View
Held by Funds
Fund positions
293
View
Short & Settlement
Short Interest Rising
Shares short
13.5M
Days to cover
7.9d
Change
+1.8M sh
View
Short Volume
Short vol %
51%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
6.5K
Value
$157.3K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$19.0M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$277.0M
Net income (FY)
$-59.5M
EPS diluted
$-0.39
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 4, 2026
This year
12
View
Proposed Sales
Value
$3.8M
Shares
142.2K
Filed
Sep 16, 2026
View
Earnings & Events
Earnings Calls
Last call
Jul 29, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jul 15, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ADPT +3.6% +18.7% — +16.0% —
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +4.3% +18.6% — +16.6% —
Key facts CIK 1478320 CUSIP 00650F109 13F (30d) 9 filings 9 filers Visit website Investor relations